Axbio Technology Files for HKEX Listing for the Third Time, Jointly Sponsored by CICC and SPDB International
NewTimeSpace News: Axbio International Limited filed a listing application with the HKEX for the third time on May 14, 2026, with China International Capital Corporation (CICC) and SPD Bank International acting as joint sponsors. Founded in 2016, it is a leading biotech company focusing on the development and commercialization of molecular diagnostic instruments and biochips. Its core product, the AxiLona EL-100, is one of the few molecular diagnostic products in China capable of electrochemical-based, multi-target, rapid, low-cost, and integrated biomolecular detection.
NewTimeSpace News: Axbio International Limited submitted a listing application to the Hong Kong Stock Exchange for the third time on May 14, 2026, with CICC and SPDB International serving as joint sponsors.
Founded in 2016, the company is a leading biotechnology company dedicated to the development and commercialization of molecular diagnostic instruments and biochips. As of the latest practicable date, its product portfolio includesone microarray chip analyzer, two EL-NGS gene sequencers, and a variety of supporting test kits, all independently developed.
The core product,AxiLona EL-100, is one of the few molecular diagnostic products in China that can perform electrochemical-based, multi-target, rapid, low-cost, and integrated biomolecular detection. It features nucleic acid detection functionality, enabling qualitative analysis of current signals generated by nucleic acid microarray chips. The company plans to expand its capabilities to include both nucleic acid and protein detection in the future.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- ALI HEALTH(00241.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at CNY 1.94 billion, YoY increase of 35.17%
- CHINAGOLDINTL(02099.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at USD 233.96 million, YoY increase of 175.2%
- MAN WAH HLDGS(01999.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 1.81 billion, YoY decrease of 12.13%
